GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Kaibao Pharmaceutical Co Ltd (SZSE:300039) » Definitions » Net Cash per Share

Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Net Cash per Share : ¥0.31 (As of Jun. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Shanghai Kaibao Pharmaceutical Co Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Shanghai Kaibao Pharmaceutical Co's Net Cash per Share for the quarter that ended in Jun. 2024 was ¥0.31.

The historical rank and industry rank for Shanghai Kaibao Pharmaceutical Co's Net Cash per Share or its related term are showing as below:

SZSE:300039' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 4.04   Med: 15.43   Max: 56.95
Current: 17.23

During the past 13 years, the highest Price-to-Net-Cash Ratio of Shanghai Kaibao Pharmaceutical Co was 56.95. The lowest was 4.04. And the median was 15.43.

SZSE:300039's Price-to-Net-Cash is ranked worse than
69.41% of 255 companies
in the Drug Manufacturers industry
Industry Median: 7.8 vs SZSE:300039: 17.23

Shanghai Kaibao Pharmaceutical Co Net Cash per Share Historical Data

The historical data trend for Shanghai Kaibao Pharmaceutical Co's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Kaibao Pharmaceutical Co Net Cash per Share Chart

Shanghai Kaibao Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.98 1.07 1.04 0.32 0.19

Shanghai Kaibao Pharmaceutical Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 0.14 0.19 0.39 0.31

Competitive Comparison of Shanghai Kaibao Pharmaceutical Co's Net Cash per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Kaibao Pharmaceutical Co's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Kaibao Pharmaceutical Co's Price-to-Net-Cash Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Kaibao Pharmaceutical Co's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Shanghai Kaibao Pharmaceutical Co's Price-to-Net-Cash falls into.



Shanghai Kaibao Pharmaceutical Co Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Shanghai Kaibao Pharmaceutical Co's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Net Cash per Share (A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(751.952-546.817-1.639)/1046
=0.19

Shanghai Kaibao Pharmaceutical Co's Net Cash per Share for the quarter that ended in Jun. 2024 is calculated as

Net Cash per Share (Q: Jun. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(781.743-460.152-1.403)/1046
=0.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Kaibao Pharmaceutical Co  (SZSE:300039) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Shanghai Kaibao Pharmaceutical Co Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Shanghai Kaibao Pharmaceutical Co's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Kaibao Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
88 Chengpu Road, Shanghai Industrial Comprehensive Development Zone, Shanghai, CHN, 201401
Shanghai Kaibao Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in research, development, production, and sales of modern Chinese medicine. The company produces traditional Chinese medicines in the form of solid dosage, oral liquids, and small volume injections. Its main product is Tanreqing injection is mainly used for pneumonia, acute and chronic bronchitis and upper respiratory tract infection.
Executives
Liu Shao Yong Supervisors
Ren Li Wang Secretary Dong
Zhang Tao Executives
Mu Jing Wei Director
Li Xiu Hai Directors, executives
Zhang Lian Xin Supervisors
Han Jing Independent director
Wang Guo Ming Directors, executives
Wang Chong Bang Executives
Liu Yi Shan Director
Li Qing Wei Independent director
Mu Lai An Director
Zhu Ying Jun Executives
Chang Qing Ling Supervisors
Zhang Peng Director

Shanghai Kaibao Pharmaceutical Co Headlines

No Headlines